Use of direct oral anticoagulants in cerebral venous thrombosis: a systematic review.
Journal
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
ISSN: 1473-5733
Titre abrégé: Blood Coagul Fibrinolysis
Pays: England
ID NLM: 9102551
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
pubmed:
18
9
2020
medline:
20
5
2021
entrez:
17
9
2020
Statut:
ppublish
Résumé
: We are here to review the efficacy and safety of direct oral anticoagulants (DOACs) in the treatment of Cerebral Venous Thrombosis (CVT). A search strategy was developed with a research librarian. All published articles including trials, studies, case series, and case reports were reviewed from NCBI/PubMed up to May 2019 by two independent reviewers. A total of 11 studies were identified, which included 70 patients with CVT on DOACs. After 6 months follow-up more than 86.7% of these patients had a good outcome on the Modified Rankin Scale (mRS) of 0--1 at 6 months and no recurrence of venous thromboembolic events (VTE) at 12 months. Recanalization rate at 6 months varied from 55 to 100%. Only two patients had a side effect of minor bleeding because of DOAC usage. Although the current American Heart Association/American Stroke Association and European Stroke Organization guidelines do not endorse the use of DOACs for treatment of CVT because of lack of evidence from large randomized clinical trials, Use of DOACs in CVT appears to be well tolerated and efficacious with favorable outcomes. Further evidence is needed to establish their use in CVT.
Identifiants
pubmed: 32941197
doi: 10.1097/MBC.0000000000000958
pii: 00001721-202012000-00001
doi:
Substances chimiques
Factor Xa Inhibitors
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
501-505Références
Bousser MG, Ferro JM. Cerebral venous thrombosis: an update. Lancet Neurol 2007; 6:162–170.
Ferro JM, Bousser MG, Canhao P, et al. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis - endorsed by the European Academy of Neurology. Eur J Neurol 2017; 24:1203–1213.
Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149:315–352.
Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369:799–808.
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139–1151.
Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981–992.
Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361:2342–2352.
Banks JL, Marotta CA. Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis. Stroke 2007; 38:1091–1096.
Herweh C, Griebe M, Geisbusch C, et al. Frequency and temporal profile of recanalization after cerebral vein and sinus thrombosis. Eur J Neurol 2016; 23:681–687.
Aguiar de Sousa D, Lucas Neto L, Canhao P, Ferro JM. Recanalization in Cerebral Venous Thrombosis. Stroke 2018; 49:1828–1835.
Ferro JM, Canhao P, Stam J, Bousser MG, Barinagarrementeria F, Investigators I. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004; 35:664–670.
Dentali F, Poli D, Scoditti U, et al. Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. J Thromb Haemost 2012; 10:1297–1302.
Bertoletti L, Benhamou Y, Bejot Y, et al. Direct oral anticoagulant use in patients with thrombophilia, antiphospholipid syndrome or venous thrombosis of unusual sites: A narrative review. Blood Rev 2018; 32:272–279.
Nalleballe K, Sharma R, Kovvuru S, et al. Why are acute ischemic stroke patients not receiving thrombolysis in a telestroke network? J Telemed Telecare 2019; 1357633X18824518.
Nalleballe K, Sharma R, Brown A, et al. Ideal telestroke time targets: Telestroke-based treatment times in the United States stroke belt. J Telemed Telecare 2018; 1357633X18805661.
Brown A, Onteddu S, Sharma R, et al. A Pilot Study Validating Video-Based Training on Pre-Hospital Stroke Recognition. J Neurol Neurosurg Psychiatry Res 2019; 1:
Covut F, Kewan T, Perez O, Flores M, Haddad A, Daw H. Apixaban and rivaroxaban in patients with cerebral venous thrombosis. Thromb Res 2019; 173:77–78.
van Den Belt AG, Prins MH, Lensing AW, et al. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2000; CD001100.
Shankar Iyer R, Tcr R, Akhtar S, Muthukalathi K, Kumar P, Muthukumar K. Is it safe to treat cerebral venous thrombosis with oral rivaroxaban without heparin? A preliminary study from 20 patients. Clin Neurol Neurosurg 2018; 175:108–111.
Ferro JM, Dentali F, Coutinho JM, et al. Rationale, design, and protocol of a randomized controlled trial of the safety and efficacy of dabigatran etexilate versus dose-adjusted warfarin in patients with cerebral venous thrombosis. Int J Stroke 2018; 13:766–770.
Hon SF, Li HL, Cheng PW. Use of direct thrombin inhibitor for treatment of cerebral venous thrombosis. J Stroke Cerebrovasc Dis 2012; 21:911–915.
Geisbusch C, Richter D, Herweh C, Ringleb PA, Nagel S. Novel factor xa inhibitor for the treatment of cerebral venous and sinus thrombosis: first experience in 7 patients. Stroke 2014; 45:2469–2471.
Mutgi SA, Grose NA, Behrouz R. Rivaroxaban for the treatment of cerebral venous thrombosis. Int J Stroke 2015; 10: (Suppl A100): 167–168.
Sugie M, Iizuka N, Shimizu Y, Ichikawa H. Cerebral Venous Thromboembolism in Antiphospholipid Syndrome Successfully Treated with the Combined Use of an Anti-Xa Inhibitor and Corticosteroid. Intern Med 2015; 54:3051–3056.
Mendonca MD, Barbosa R, Cruz-e-Silva V, Calado S, Viana-Baptista M. Oral direct thrombin inhibitor as an alternative in the management of cerebral venous thrombosis: a series of 15 patients. Int J Stroke 2015; 10:1115–1118.
Cho YH, Chae MK, Cha JM, et al. Cerebral venous thrombosis in a patient with Crohn's disease. Intest Res 2016; 14:96–101.
Anticoli S∗ PF, Scifoni G, Ferrari C, Pozzessere C. Treatment of cerebral venous thrombosis with rivaroxaban. Journal of Biomedical Sciences 2016; 5:
Rao SK, Ibrahim M, Hanni CM, et al. Apixaban for the treatment of cerebral venous thrombosis: a case series. J Neurol Sci 2017; 381:318–320.
Cappellari M, Bovi P. Direct oral anticoagulants in patients with cervical artery dissection and cerebral venous thrombosis. a case series and review of the literature. Int J Cardiol 2017; 244:282–284.